Liquidia Technologies (NASDAQ: LQDA) is one of 122 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Liquidia Technologies to similar companies based on the strength of its earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.
This is a breakdown of current ratings and price targets for Liquidia Technologies and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Liquidia Technologies Competitors||822||2836||5005||252||2.53|
Earnings & Valuation
This table compares Liquidia Technologies and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Liquidia Technologies||$2.71 million||-$53.14 million||-1.17|
|Liquidia Technologies Competitors||$1.48 billion||$146.54 million||42.16|
Liquidia Technologies’ peers have higher revenue and earnings than Liquidia Technologies. Liquidia Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
46.8% of Liquidia Technologies shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 4.3% of Liquidia Technologies shares are held by insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Liquidia Technologies and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Liquidia Technologies Competitors||-504.98%||-46.01%||-15.86%|
Liquidia Technologies Company Profile
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.